DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse (NIDA)
...about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
read moreInterveXion Names Industry Veteran Keith W. Ward as President and Chief Executive Officer
Little Rock, AR (20 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced that its Board of Managers has appointed Keith W. Ward, Ph.D., to serve as...
read moreInterveXion Announces Expansion of Executive Leadership Team
Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team...
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse (NIDA)
...about half of people who experience a mental illness will also experience a substance use disorder at some point in their lives and vice versa. Source: DrugFacts: Comorbidity: Substance Use Disorders and Other Mental Illnesses | National Institute on Drug Abuse...
read moreInterveXion Names Industry Veteran Keith W. Ward as President and Chief Executive Officer
Little Rock, AR (20 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced that its Board of Managers has appointed Keith W. Ward, Ph.D., to serve as...
read moreInterveXion Announces Expansion of Executive Leadership Team
Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team...
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.